At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing ...
Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around ...
PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...
Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains. The rise in cell ...
Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain ...
Gross-to-net concessions exceeding half of U.S. brand revenue make minor contracting and payment inefficiencies translate into hundreds of millions in leakage or compliance risk. Legacy revenue ...
Raquel Vazquez discusses how data can be incorporated to make key decisions within the cold chain.
Structural disruption pressures are rising, making safety stock and excess capacity insufficient as primary risk buffers across highly regulated, temperature-sensitive networks. Digital-twin ...
EPS for ~3-day lanes, polyurethane for higher performance, and vacuum insulation panels for maximum duration—still anchor ...
Pharmaceutical cold chain logistics is entering a phase where data quality and decision speed matter as much as physical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results